中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
12期
1761-1763
,共3页
卵巢癌%耐药%顺铂%硼替佐米%细胞周期%凋亡
卵巢癌%耐藥%順鉑%硼替佐米%細胞週期%凋亡
란소암%내약%순박%붕체좌미%세포주기%조망
Ovarian cancer%Drug resistance%Cisplatin%Bortezomib%Cell cycle%Apoptosis
目的 探讨硼替佐米对人卵巢癌耐顺铂细胞株(SKOV3/DDP)的逆转作用及其可能机制.方法 体外培养人卵巢癌细胞株(SKOV3)和SKOV3/DDP,空白对照组加RPMI-1640完全培养基;硼替佐米组浓度分别为0.0625、0.1250、0.2500、0.5000、1.0000、2.0000 μmol/L,检测不同作用时间对SKOV3/DDP的生长抑制情况;采用流式细胞术检测0.5000μmol/L硼替佐米作用后细胞周期及凋亡率的变化.结果①硼替佐米对SKOV3/DDP细胞生长抑制情况:0.0625、0.1250、0.2500、0.5000、1.0000、2.0000 μmol/L的硼替佐米作用SKOV3/DDP细胞24 h的生长抑制率依次为(1.19±0.07)％、(2.24±0.08)％、(3.47±0.20)％、(4.61±0.07)％、(5.80±0.17)％、(6.43 ±0.10)％;作用48 h的生长抑制率依次为(9.39±0.08)％、(12.17±0.23)％、(18.08±0.25)％、(41.11±0.10)％、(55.45±0.41)％、(64.91±0.18)％;作用72 h的生长抑制率依次为(13.21±0.32)％、(20.18±0.23)％、(22.91 ±0.35)％、(52.08 ±0.10)％、(76.59±0.39)％、(83.23±0.38)％.空白对照组抑制率为0,各实验组与空白对照组之间两两比较,差异均有统计学意义(均P＜0.05).②细胞周期及凋亡率的变化情况:0.5000 μmol/L硼替佐米作用SKOV3/DDP细胞48 h,细胞周期G2/M期的比例为22.8％,空白对照组为10.1％,差异有统计学意义(P＜0.05);凋亡率分别为11.7％和2.2％,差异有统计学意义(P＜0.05).结论硼替佐米能够逆转SKOV3/DDP细胞的耐药作用;并将SKOV3/DDP的细胞周期阻滞于G2/M期.
目的 探討硼替佐米對人卵巢癌耐順鉑細胞株(SKOV3/DDP)的逆轉作用及其可能機製.方法 體外培養人卵巢癌細胞株(SKOV3)和SKOV3/DDP,空白對照組加RPMI-1640完全培養基;硼替佐米組濃度分彆為0.0625、0.1250、0.2500、0.5000、1.0000、2.0000 μmol/L,檢測不同作用時間對SKOV3/DDP的生長抑製情況;採用流式細胞術檢測0.5000μmol/L硼替佐米作用後細胞週期及凋亡率的變化.結果①硼替佐米對SKOV3/DDP細胞生長抑製情況:0.0625、0.1250、0.2500、0.5000、1.0000、2.0000 μmol/L的硼替佐米作用SKOV3/DDP細胞24 h的生長抑製率依次為(1.19±0.07)％、(2.24±0.08)％、(3.47±0.20)％、(4.61±0.07)％、(5.80±0.17)％、(6.43 ±0.10)％;作用48 h的生長抑製率依次為(9.39±0.08)％、(12.17±0.23)％、(18.08±0.25)％、(41.11±0.10)％、(55.45±0.41)％、(64.91±0.18)％;作用72 h的生長抑製率依次為(13.21±0.32)％、(20.18±0.23)％、(22.91 ±0.35)％、(52.08 ±0.10)％、(76.59±0.39)％、(83.23±0.38)％.空白對照組抑製率為0,各實驗組與空白對照組之間兩兩比較,差異均有統計學意義(均P＜0.05).②細胞週期及凋亡率的變化情況:0.5000 μmol/L硼替佐米作用SKOV3/DDP細胞48 h,細胞週期G2/M期的比例為22.8％,空白對照組為10.1％,差異有統計學意義(P＜0.05);凋亡率分彆為11.7％和2.2％,差異有統計學意義(P＜0.05).結論硼替佐米能夠逆轉SKOV3/DDP細胞的耐藥作用;併將SKOV3/DDP的細胞週期阻滯于G2/M期.
목적 탐토붕체좌미대인란소암내순박세포주(SKOV3/DDP)적역전작용급기가능궤제.방법 체외배양인란소암세포주(SKOV3)화SKOV3/DDP,공백대조조가RPMI-1640완전배양기;붕체좌미조농도분별위0.0625、0.1250、0.2500、0.5000、1.0000、2.0000 μmol/L,검측불동작용시간대SKOV3/DDP적생장억제정황;채용류식세포술검측0.5000μmol/L붕체좌미작용후세포주기급조망솔적변화.결과①붕체좌미대SKOV3/DDP세포생장억제정황:0.0625、0.1250、0.2500、0.5000、1.0000、2.0000 μmol/L적붕체좌미작용SKOV3/DDP세포24 h적생장억제솔의차위(1.19±0.07)％、(2.24±0.08)％、(3.47±0.20)％、(4.61±0.07)％、(5.80±0.17)％、(6.43 ±0.10)％;작용48 h적생장억제솔의차위(9.39±0.08)％、(12.17±0.23)％、(18.08±0.25)％、(41.11±0.10)％、(55.45±0.41)％、(64.91±0.18)％;작용72 h적생장억제솔의차위(13.21±0.32)％、(20.18±0.23)％、(22.91 ±0.35)％、(52.08 ±0.10)％、(76.59±0.39)％、(83.23±0.38)％.공백대조조억제솔위0,각실험조여공백대조조지간량량비교,차이균유통계학의의(균P＜0.05).②세포주기급조망솔적변화정황:0.5000 μmol/L붕체좌미작용SKOV3/DDP세포48 h,세포주기G2/M기적비례위22.8％,공백대조조위10.1％,차이유통계학의의(P＜0.05);조망솔분별위11.7％화2.2％,차이유통계학의의(P＜0.05).결론붕체좌미능구역전SKOV3/DDP세포적내약작용;병장SKOV3/DDP적세포주기조체우G2/M기.
Objective To investigate the possible mechanisms that how bortezomib reverses the drug resistance of cisplatin-resistant human ovarian cancer cell lines (SKOV3/DDP).Methods The resistant cell line-SKOV3/DDP and cell line-SKOV3 were chosen in vitro culture with different final density of bortezomib (0.0625,0.1250,0.2500,0.5000,1.0000,2.0000 μmol/L).Different density and different action time of bortezomib were measured to investigate the impact on the growth suppression of SKOV3/DDP cell.The impact of 0.5000 μmol/L bortezomib on the cell cycle and cell apoptosis of SKOV3/DDP and SKOV3 cell was measured by flow cytometry assay.Results ①After SKOV3/DDP cell in vitro culture with 0.0625,0.1250,0.2500,0.5000,1.0000,2.0000 μμ mol/L bortezomib for 24 h,the rate of SKOV3/DDP cell growth suppression was (1.19 ±0.07)％,(2.24 ±0.08)％,(3.47 ±0.20)％,(4.61 ±0.07)％,(5.80 ±0.17％),(6.43 ±0.10)％ respectively;(9.39 ±0.08)％,(12.17 ±0.23)％,(18.08 ±0.25)％,(41.11 ±0.10)％,(55.45 ±0.41)％,(64.91 ±0.18)％ after acting for 48 h; (13.21 ±0.32)％,(20.18 ± 0.23)％,(22.91 ±0.35)％,(52.08 ±0.10)％,(76.59 ± 0.39) ％,(83.23 ± 0.38) ％ after acting for 72 h.The different rate had statistical significant between experimental group and control group (P ＜ 0.05).②After 0.5000 μmol/L bortezomib acting with SKOV3/DDP cells for 48 h,cell cycle G2/M phase ratio was 22.8％ ;the control group was 10.1％ and the difference had statistically significant (P ＜ 0.05) ; apoptosis rates were 11.7％ and 2.2％ ; the difference was statistically significant (P ＜0.05).Conclusions Bortezomib can reverse the drug resistance of SKOV3/DDP.Bortezomib can block the cell cycle of cell line-SKOV3/DDP at the stage of G2/M.
